Aug. 15 at 11:51 AM
$VTGN without a partnership or strategic agmt such as RM or business combination, RS + recapitalization needed to fund trials imo, Fasedienol ph3 if ever approved by FDA would take 1 year to produce topline results, Co. stated cash enough to 2027 summer, not beyond.
Fasedienol approval, when and If, in late 2028 and commercialization only in 2029, Company in the meantime will need at least 60/80 mln USD imo to fund SG RD expenses.Serious oneoff recapitalization or severe dilution ahead.
"Cash, cash equivalents, and marketable securities were
$31.7 million as of June 30, 2026. Based on current operating plans, Vistagen believes its cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027 but are not expected to be sufficient to extend the Company’s cash runway for more than a year from now."
https://www.otcmarkets.com/stock/VTGN/news/Vistagen-Reports-Fiscal-Year-2027-First-Quarter-Financial-Results-and-Corporate-Update?e&id=3522210
